The chemosensitivity testing is important in the research of cancer biology, development and screening of anticancer drug, and improvement of chemotherapy modalities. Subrenal capsule tumor implant assay (SRCA) is a promising rapid method in the selection of individual chemotherapy for cancer patients clinically. A total of 100 SRCA were performed with several gynecologic malignancies(69 cervical, 10 ovarian, 10 endometrial carcinomas, 6 vulva carcinoma, 4 sarcoma, and 1 choriocarcinoma). 1 mm x 1 mm x 1 mm fragments oi fresh human gynenologic tumors were implanted under the renal capsule of immunocompetent female adult BALB-C mice and tested against several chemotherapeutic agents or their combinations. An average of 75% of tumors showed positive growth. The evaluable assay rate was 91%(91/100). Variable response rate were noted in each gynenologic tumor. An overall predictive accuracy rate of SRCA was 73% in present series. In conclusion, the SRCA is considered as a reliable in vivo clinical chemosensitivity test in the selection of individual cancer chemotherapy.
PDF Links
Full text via DOI 
Download Citation 
